Key TxCell patent to be granted in the US for its lead product Ovasave(R)
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
List view / Grid view
News
First treatment approved under EAMS developed using antibody humanization expertise at UK’s MRC Technology
11 March 2015 | By MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma...
TATAA Biocenter introduces partnership with Qlucore to use Qlucore Omics Explorer in its Next Generation Sequencing courses
10 March 2015 | By TATAA Biocenter and Qlucore
TATAA Biocenter, the world's premier organizer of hands-on training in molecular diagnostics and Europe´s leading provider of genomic services, has announced a partnership with Qlucore for the analyses of Next Generation Sequencing (NGS) data...
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer’s disease
9 March 2015 | By Probiodrug
First patient enrolled at leading Alzheimer Center in Amsterdam...
Phico Therapeutics receives Translation Award to advance its SASPject™ PT4 aimed at Escherichia coli and Klebsiella pneumoniae towards clinical trials
9 March 2015 | By Phico Therapeutics
Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25M Translation Award by the Wellcome Trust to develop its SASPject™ PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae...
ORYX successfully completes Phase I/IIa trial with therapeutic vaccine VicOryx to treat HPV-associated cancers
9 March 2015 | By ORYX
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine VicOryx to treat p16INK4a-overexpressing HPV- (Human Papilloma Virus-) positive cancer patients in an open label, single center trial that included 26 patients...
University spin-out gets crowdfunding investment to develop a cure for Parkinson’s Disease
9 March 2015 | By Edinburgh Research and Innovation
University of Edinburgh spin-out company Parkure Ltd has successfully attracted over £75,000 in crowdfunding investment through ShareIn, the technology-focussed crowdfunding firm, to develop a cure for Parkinson’s disease...
Baxter’s Bioscience Business acquires biopharmaceutical company SuppreMol
6 March 2015 | By Baxter International Inc. / SuppreMol
Acquisition includes SuppreMol's early-stage pipeline of protein therapeutics for autoimmune and allergic diseases...
Combination cell-gene therapy for lung cancer to be tested in UK patients
6 March 2015 | By The Medical Research Council
A pioneering new combined cell-gene therapy to treat lung cancer will be tested in NHS patients this year, after receiving £2m of Biomedical Catalyst funding from the Medical Research Council...
ChemInteract consortium wins funding to develop chemical toxicity assessment tool
4 March 2015 | By Retrogenix
New technology aims to reduce animal testing and improve safety testing of chemicals...
‘Stem cell’ test could identify most aggressive breast cancers
4 March 2015 | By The Institute of Cancer Research
Testing breast cancer cells for how closely they resemble stem cells could identify women with the most aggressive disease, a new study suggests...
Manipulating cells’ shapes could treat breast cancer
4 March 2015 | By The Institute of Cancer Research
Changing the shape of breast cancer cells could make the disease more sensitive to treatments – even driving the body’s own inflammatory response against a tumour – a new study shows...
Domain Therapeutics launches Specific Purpose Vehicle Kaldi Pharma to harness the potential of its adenosine programs
4 March 2015 | By Domain Therapeutics
Kaldi Pharma granted its first license to CleveXel Pharma, who will develop a preclinical candidate for Parkinson’s disease...
Northern Health Science Alliance welcomes funding to boost life and health sciences in the North of England
4 March 2015 | By The Northern Health Science Alliance
The NHSA’s ambitious project of establishing an internationally recognised life science and healthcare economy in the North of England has been given a vital boost following funding from HEFCE...
ORYX’ therapeutic vaccine MicOryx successfully completes Phase I/IIa trial to treat MSH-H colorectal cancer
4 March 2015 | By ORYX
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine MicOryx to treat advanced microsatellite instable (MSI-H-) colorectal cancer patients in an open label, single center trial that included 22 patients (UICC stage III or…